Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005890
Disease: Body Height
Body Height
0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0205682
Disease: Waist-Hip Ratio
Waist-Hip Ratio
0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.040 Biomarker group BEFREE EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. 30867289 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.040 Biomarker group BEFREE Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma. 30343511 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma. 30343511 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. 30867289 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.040 Biomarker group BEFREE Notably, this combination also exhibited strong synergy in prostate cancer cells.<b>Conclusions:</b> Our results identify dual inhibition of EZH2 and EZH1 together with proteasome inhibition as a promising epigenetics-based therapy for PRC2-dependent cancers.<i>Clin Cancer Res; 23(16); 4817-30.©2017 AACR</i>. 28490465 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.040 Biomarker group BEFREE A solid cancer panel assay demonstrated that some cancer cell lines are sensitive to EZH1/2 dual inhibitor in vitro and in vivo. 28741798 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE Notably, this combination also exhibited strong synergy in prostate cancer cells.<b>Conclusions:</b> Our results identify dual inhibition of EZH2 and EZH1 together with proteasome inhibition as a promising epigenetics-based therapy for PRC2-dependent cancers.<i>Clin Cancer Res; 23(16); 4817-30.©2017 AACR</i>. 28490465 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE A solid cancer panel assay demonstrated that some cancer cell lines are sensitive to EZH1/2 dual inhibitor in vitro and in vivo. 28741798 2017
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute
0.030 AlteredExpression disease BEFREE EZH1/2 expression and mutation were analysed in 200 patients with AML. 31794134 2020
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute
0.030 Biomarker disease BEFREE Our analysis implicated <i>BCL2</i> expression level as an important indicator of venetoclax responsiveness and provided a rationale for its targeting in specific leukemia subtypes and multiple myeloma, linked several polycomb group proteins that could be targeted by small molecules (SFMBT1, CBX7, and EZH1) with chronic lymphocytic leukemia, and supported <i>CDK6</i> as a disease-specific target in acute myeloid leukemia. 30940663 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.030 Biomarker disease BEFREE Polycomb repressive complex 2 (PRC2) components, EZH2 and its homolog EZH1, and PI3K/Akt signaling pathway are focal points as therapeutic targets for multiple myeloma. 31571328 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.030 Biomarker disease BEFREE Our results show the role of EZH1/2 in the maintenance of myeloma stem cells and provide a preclinical rationale for therapeutic application of OR-S1, leading to significant advances in the treatment of MM. 30343511 2019
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute
0.030 GeneticVariation disease BEFREE Genetic deletion of Ezh1/2 in a mouse AML model induced cell cycle progression of quiescent LSCs and differentiation to LSCs, eventually eradicating AML LSCs. 28951561 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.030 Biomarker disease BEFREE Here, we investigated the preclinical effects of UNC1999, a dual inhibitor of EZH2 and EZH1, in combination with proteasome inhibitors on multiple myeloma and prostate cancer.<b>Experimental Design:</b><i>In vitro</i> and <i>in vivo</i> efficacy of UNC1999 and the combination with proteasome inhibitors was evaluated in multiple myeloma cell lines, primary patient cells, and in a xenograft model. 28490465 2017
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.020 Biomarker group BEFREE Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. 31747604 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 GeneticVariation group BEFREE Two hotspots of EZH1 mutations were only found in RAS-negative follicular-patterned tumors. 29723601 2018
CUI: C0151468
Disease: Thyroid Gland Follicular Adenoma
Thyroid Gland Follicular Adenoma
0.020 GeneticVariation disease BEFREE EZH1 mutations were detected in 3% of follicular adenoma and in 20% of Hürthle cell adenoma, and one minimally invasive Hürthle cell carcinoma. 29723601 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.020 Biomarker group BEFREE A hematological cancer panel assay indicated that EZH1/2 dual inhibitor has efficacy against some lymphomas, multiple myeloma, and leukemia with fusion genes such as MLL-AF9, MLL-AF4, and AML1-ETO. 28741798 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 Biomarker group BEFREE Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition. 28490465 2017
CUI: C0151468
Disease: Thyroid Gland Follicular Adenoma
Thyroid Gland Follicular Adenoma
0.020 GeneticVariation disease BEFREE Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas. 27500488 2016
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.010 Biomarker disease BEFREE Finally, the role of microRNA-765/EZH1 axis in the progression of BCa was assessed. 31396353 2019
CUI: C0023418
Disease: leukemia
leukemia
0.010 PosttranslationalModification disease BEFREE Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. 31699991 2019
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.010 Biomarker disease BEFREE Our analysis implicated <i>BCL2</i> expression level as an important indicator of venetoclax responsiveness and provided a rationale for its targeting in specific leukemia subtypes and multiple myeloma, linked several polycomb group proteins that could be targeted by small molecules (SFMBT1, CBX7, and EZH1) with chronic lymphocytic leukemia, and supported <i>CDK6</i> as a disease-specific target in acute myeloid leukemia. 30940663 2019